HANGZHOU, China, Dec. 9, 2019 /PRNewswire/ -- BJ Bioscience Inc. (the 'company') today announced that the first patient was successfully dosed on December 4, 2019 in the first-in-human (FIH) trial of the company's BJ-001 program at NEXT ONCOLOGY in San Antonio, Texas.

Release time: 12-10

The new partnership will combine the research and development ingenuity of BJ Bioscience with the state-of-art biologics manufacturing set up of CMABCMAB will provide full developm

Release time: 10-31

BJ Bioscience Inc.announced that the world's first tumor-targeted IL-15 fusion protein (product code BJ-001), independently developed by the company and having global patents, was

Release time: 09-20